Presentation on theme: "Shedding light on Restless Legs Syndrome via the Human Genome David Rye, MD, PhD Professor of Neurology Director, Emory Healthcare Program in Sleep Shedding."— Presentation transcript:
Shedding light on Restless Legs Syndrome via the Human Genome David Rye, MD, PhD Professor of Neurology Director, Emory Healthcare Program in Sleep Shedding light on Restless Legs Syndrome via the Human Genome: Pharmacogenomic Implications David B. Rye Professor of Neurology Director, Emory University Program in Sleep Atlanta, GA
RLS Affects Tens of Millions in the United States alone RLS is more prevalent than originally believed 1 –RLS affects approximately 10% of the US adult population, yet often goes undiagnosed 2 –Approximately 12 million Americans suffer from moderate to severe ‘primary’ RLS 2,3 1.Hening W. Clin Neurophysiol. 2004;115: Hening W, et al. Sleep Med. 2004;5: NINDS, NIH; NIH Publication No
Burden of RLS is Significant Depressed mood (OR = 2.6) Stroke & Cardiovascular disease (OR= ) Hypertension (OR = 1.5; * PLMs > 30/hr OR = 2.3) Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001;16: Winkelman J, Finn L, Young T. Prevalence and correlates of restless legs syndrome in the Wisconsin sleep cohort. Sleep 2005;28(Abst Suppl):A – Sleep Medicine 2006-May 30 th (epub ahead of print) * Personal observations; Winkelman et al. (2008) Neurology 70:35-42
RLS remains a clinical diagnosis: IRLSSG/NIH Diagnostic Criteria for RLS Urge to move legs, usually accompanied by uncomfortable leg sensations Onset or worsening of symptoms at rest or inactivity, such as when lying or sitting Relief with movement—partial or total relief from discomfort by walking or stretching Worsening of symptoms in the evening and at night Allen RP, et al, for the International Restless Legs Syndrome Study Group. Sleep Med. 2003;4:
Periodic leg movements in sleep (PLMs) in RLS appear to exhibit heritability (at least as much as, if not more than, sensory symptoms)!
Iron is central to RLS symptomatology RLS symptoms occur in > 40% of subjects with iron deficiency Akyol et al., Clin Neurol Neurosurg Dec;106: In vivo and in vitro iron depletion in dopamine rich brain regions of RLS patients Allen et al., Neurology Jan 56: Connor et al., Neurology Aug 61: Iron deficiency adversely affects dopamine signaling Allen et al, Sleep Med Jul 5: Oral and intravenous iron can ameliorate RLS symptoms. Earley, Heckler and Allen Sleep Med May 5:
IRON RLS Patient Iron trafficking appears to be awry in RLS/PLMs – A “leaky” bucket Earley, Heckler and Allen, Sleep Medicine (2005) 6: 301
Treatment Options Oral or intravenous iron repletion when iron deficiency confirmed (9-50% of cases) Dopaminergics – 1 st line treatment as per American Sleep Disorders Assoc. Standards of Practice Committee and the Medical Advisory Board of the RLS Foundation Pramipexole ( mg) – Ropinirole ( mg) minutes before typical symptom onset– FDA approved for idiopathic, moderate-severe RLS Off-label: Opioids – Anticonvulsants – gabapentin Benzodiazepines –
Homogeneity Excellent genealogic records Excellent record keeping in health care Highest literacy rate in the world Participation in clinical studies is high (80-85%) A genetic-linkage analysis of RLS in Iceland Funded in part by the Restless Legs Syndrome Foundation in collaboration with deCODE Genetics, Reykjavik, Iceland
4 recently identified gene variants account for at least 80% of the population attritubable risk for RLS
To everyone’s surprise/dismay: None of the implicated genes directly or indirectly affect iron or dopamine. The implicated regions are intronic or intergenic and suggest regulatory roles. The functions are in many cases not well known.
SNPs associating to RLS are intimately related to the disease biology: Multiple SNPs in at least the BTBD9 and Meis1 genes are related in a dose dependent fashion to PLMs – bearing ZERO relationship to RLS rating scales Multiple SNPs in the BTBD9 gene are inversely related in a dose dependent fashion to low iron stores At-risk SNP frequencies in disparate ethnic groups mirrors the large range of ethnic differences in RLS prevalence
RLS at-risk variants are COMMON and considerably impact population risk for RLS Allele Gene ORFrequency PARp value BTBD (0.656) x10 -7 – 1x MEIS (0.114) ~0.201x10 -3 – 8x MAP2K (0.692) ~0.341x10 -2 – 6x10 -5 PTPRD (0.13) <0.10 (X.XX) = allele frequency in Icelandic population controls
Younger or Asian Homozygous for BTBD9 Uremia
Pondering the Genetics Landscape: Will genotypes correlate with specific phenotypes? Can genetic testing inform diagnosis and treatment decisions? What are the downstream molecular networks that effect disease expression?
Pharmacogenics for RLS – targets? Treatment stratification Dopaminergics vs. opioids vs. iron vs. ? Complication stratification Dopaminergic augmentation Aggravators (e.g., antihistamines; metaclopramide) Predictive Health End-Stage Renal Disease Pregnancy
RLS pharmacogenomics - challenges RLS genes Despite high ORs, commonality of at-risk SNPs necessitates large ( ) sample sizes Choice of (endo) phenotype Latent or incipient disease Non-RLS genes
Dissecting disease biology
Acknowledgements Emory Program in SleepEmory Dept. of Cell BiologydeCODE Genetics Dr. Donald BliwiseDr. S. Sanyal Dr. Hreinn Stefansson Dr. Michael Decker Dr. KristleifurKristjansson Dr. Alex IranzoEmory Dept. of Genetics Dr. Andrew Hicks Dr. Jeffrey DurmerDr. Steve Warren Dr. Larus Gudmundsson Dr. Lynn-Marie TrottiDr. Mark Bouzyk Ingibjorg Eiriksdottir, RN Dr. Lisa Billars Dr. Jeffrey Gulcher Dr. Reddiah Mumanenni Dr. Kari Stefansson Dr. Glenda KeatingEmory Dept. of Neurology Dr. Amanda FreemanDr. Allan LeveyLandspitali Dr. Tom GenettaDr. Salina Waddy J Max BeckAmi Rosen Dr. Thordur Sigmundsson Gillian HueCRIN Staff Dr. Albert Pal Sigdursson Daniel Miller Kaniyika FreemanEmory School of Public Health Dr. Harland AustinFunding RLS Foundation Arthur L. Williams Jr. Foundation Woodruff Health Sciences